Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2021 | Lung Cancer | Correction

Correction to: Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner

Authors: Shengming Deng, Guoxi Zhang, Jiajie Kuai, Peng Fan, Xuexiang Wang, Pei Zhou, Dan Yang, Xichen Zheng, Xiaomei Liu, Qunli Wu, Yuhui Huang

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Excerpt

Correction to: J Exp Clin Cancer Res 37, 260 (2018) …

Deng S, Zhang G, Kuai J, et al. Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner. J Exp Clin Cancer Res. 2018;37:260 https://doi.org/10.1186/s13046-018-0932-y.CrossRef

Title: Correction to: Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner
Authors: Shengming Deng
Guoxi Zhang
Jiajie Kuai
Peng Fan
Xuexiang Wang
Pei Zhou
Dan Yang
Xichen Zheng
Xiaomei Liu
Qunli Wu
Yuhui Huang
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Lung Cancer
Lung Cancer
Lung Cancer
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-021-02170-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2021

PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models

Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

The component of the m6A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors

ZIP10 drives osteosarcoma proliferation and chemoresistance through ITGA10-mediated activation of the PI3K/AKT pathway

DNMT1-induced miR-378a-3p silencing promotes angiogenesis via the NF-κB signaling pathway by targeting TRAF1 in hepatocellular carcinoma

Correction to: Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer